Spruce Biosciences, Inc. (SPRB)
| Market Cap | 140.02M +2,878.3% |
| Revenue (ttm) | n/a |
| Net Income | -51.35M |
| EPS | -36.05 |
| Shares Out | 2.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,188 |
| Open | 49.22 |
| Previous Close | 49.02 |
| Day's Range | 47.54 - 49.31 |
| 52-Week Range | 7.26 - 240.00 |
| Beta | 3.36 |
| Analysts | Strong Buy |
| Price Target | 148.00 (+203.22%) |
| Earnings Date | Aug 12, 2026 |
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sle... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SPRB stock is "Strong Buy." The 12-month stock price target is $148.0, which is an increase of 203.22% from the latest price.
News
Spruce Biosciences management to meet virtually with B. Riley
Virtual Meeting to be held on September 28 hosted by B. Riley.
Spruce Biosciences initiated with a Buy at Lake Street on Sanfilippo asset
As previously reported, Lake Street analyst Daniel Brims initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $149 price target Spruce is developing drugs for rare diseases, notes…
Spruce Biosciences initiated with a Buy at Lake Street
Lake Street initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $149 price target
Spruce Biosciences management to meet virtually with Craig-Hallum
Virtual Meeting to be held on September 24 hosted by Craig-Hallum.
Spruce Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The session highlighted a late-stage enzyme therapy for MPS IIIB, showing robust efficacy and safety, with FDA alignment on surrogate endpoints and a BLA submission planned for Q4 2026. Early treatment improves cognition and motor skills, and global commercialization is planned.
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences announces launch of MPS3BStudy.com
Spruce Biosciences (SPRB) announced the launch of MPS3BStudy.com. The website enables families and caregivers to learn about, and register their interest in, the planned Expanded Access Program and Tr...
Spruce Biosciences Announces Launch of MPS3BStudy.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for n...
Spruce Biosciences price target lowered to $104 from $123 at Guggenheim
Guggenheim lowered the firm’s price target on Spruce Biosciences (SPRB) to $104 from $123 and keeps a Buy rating on the shares. The company is advancing TA-ERT toward a BLA…
Cure Sanfilippo, National MPS agree to make $5.5M investment in Spruce
Spruce Biosciences (SPRB) announced that Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5M strategic investment in Spruce. The proceeds will be used to…
Spruce Biosciences reports Q2 EPS ($6.68), consensus ($5.93)
“The second quarter was a period of significant execution as we advanced TA-ERT toward our planned BLA submission in the fourth quarter, which would be a transformative milestone for Spruce…
Spruce Biosciences sees cash runway into 2H27
Cash and cash equivalents as of June 30, 2026 were $96.3 million, compared to $48.9 million as of December 31, 2025. Spruce believes that its cash and cash equivalents as…
Spruce Biosciences price target lowered to $144 from $150 at Citizens
Citizens lowered the firm’s price target on Spruce Biosciences (SPRB) to $144 from $150 and keeps an Outperform rating on the shares. The firm remains optimistic on TA-ERT’s approvability given…
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological ...
Spruce Biosciences Quarterly report: Q2 2026
Spruce Biosciences has published its Q2 2026 quarterly earnings report on August 12, 2026.
Spruce Biosciences Earnings release: Q2 2026
Spruce Biosciences released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development
Spruce Biosciences (SPRB) announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development. Cohen Pfeffer joins Spruce from BioMarin Pharmaceutical (BMRN), where she s...
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializi...
Spruce Biosciences appoints Quartel as Chief Medical Officer
Spruce Biosciences (SPRB) announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Quartel joins Spruce from Zevra Therapeutics (ZVRA), where he served as Ch...
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializi...
Spruce Biosciences initiated with a Buy at B. Riley
B. Riley initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $160 price target Spruce shares are about 75% below post-FDA-alignment levels and it’s eligible Priority Review Voucher,…
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences joins Russell 3000 Index
Spruce Biosciences (SPRB) announced that it has been added as a member of the Russell 3000 Index, effective with the opening of U.S. equity markets today, in connection with the…